GlassScriptPhysician profile
Shady M Megala
NPI 1447467451
$2,767.54
in general payments reported to CMS, 2019-2025
15 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $168 · 2021: $463 · 2022: $188 · 2023: $576 · 2024: $574 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $600.28 | 2023-2025 | Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $327.51 | 2019-2024 | Breztri |
| Janssen Pharmaceuticals, INC | $299.59 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $248.22 | 2021-2024 | |
| Pfizer INC. | $247.28 | 2020-2025 | |
| Paratek Pharmaceuticals, INC. | $240.51 | 2024-2025 | Nuzyra |
| Otsuka America Pharmaceutical, INC. | $194.91 | 2019-2020 | |
| Melinta Therapeutics, LLC | $180.56 | 2022-2025 | Kimyrsa, Rezzayo, Vabomere |
| Axsome Therapeutics, INC. | $124.74 | 2025 | Symbravo |
| E.R. Squibb & Sons, L.L.C. | $113.28 | 2019-2023 | Eliquis |
| Abbvie INC. | $111.78 | 2022-2023 | |
| Scpharmaceuticals INC. | $22.03 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $20.17 | 2024 | Exparel |
| Merck Sharp & Dohme LLC | $18.62 | 2023 | Bridion |
| Allergan, INC. | $18.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shady Megala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.